India Pharma Outlook Team | Wednesday, 17 December 2025
Odisha has declared a policy on drugs and medical equipment to bring investments of 25000 crore by 2030. The policy reflects the desire of the state in turning into a large life-sciences hub in eastern India.
It was unveiled during the Odisha Pharma Summit and is aimed at the increased production of the area and establishment of a favorable climate to pharmaceutical and medical-technological enterprises.
The policy is expected to generate approximately one hundred thousand jobs both directly and indirectly as a result of the investments in pharmaceuticals, bulk drugs, formulations, and medical devices. Since the Indian country continues to import a significant amount of its medical equipment, the policy assists the state of Odisha to substitute imports and grow local production.
Also Read: Advancing Interventional Radiology in India Through Collaboration
To companies, the policy has cost advantages in the form of capital subsidies, land incentives as well as infrastructure support. Companies which establish plants can receive assistance about the expenses of plants and machinery, and subsidies regarding power supply. Local creation of jobs lowers the cost of land, and also increases skill development within the state.
One of the key aspects of the policy is infrastructure. Odisha intends to construct Pharma and MedTech Parks compliant with GMFs and capable of accommodating the active pharmaceutical ingredient, vaccines, diagnostics, implants and digital health device manufacturers. The aim of these parks is to simplify the process of entering business by large corporations as well as small scale manufacturers.
There has been an initial interest with investment commitments of approximately 5,000 crore being signed in the course of the summit. To drug and medical-device companies that are interested in expanding, Odisha is an inexpensive, policy-supported option with a long-term growth potential.
